Stocktoria

SAB Biotherapeutics, Inc. SABS

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-12

SAB Biotherapeutics, Inc. statistics & valuation

Market cap$290.6M
P / E21.9×
P / B1.9×
Return on equity8.8%
Return on capital-30.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
37.20% -22.00% -121.00% -1700.60% -3244.90% 202020212022202320242025
Return on equity (%)
51.60% -44.50% -60.30% -73.60% -131.30% 8.80% 202020212022202320242025
Shares outstanding
27.0M 43.5M 5.0M 9.2M 9.3M 61.3M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
35.60% -21.10% -36.80% -50.30% -77.20% 7.70% 202020212022202320242025
Free cash flow margin (%)
-4.90% -14.70% -107.20% -1130.70% -2618.60% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
$0.74 -$0.63 -$4.31 -$7.64 -$3.68 -$0.79 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin—-3244.9%-1700.6%-121.0%-22.0%37.2%
Net margin—-2579.0%-1884.5%-78.4%-28.2%36.4%
FCF margin—-2618.6%-1130.7%-107.2%-14.7%-4.9%
Return on assets7.7%-77.2%-50.3%-36.8%-21.1%35.6%
Return on equity8.8%-131.3%-73.6%-60.3%-44.5%51.6%
Current ratio9.462.985.451.471.903.11

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.